Eloxx Pharmaceuticals マネジメント

マネジメント基準チェック /34

Eloxx Pharmaceuticalsの CEO はSumit Aggarwalで、 Apr2021年に任命され、の在任期間は 3.58年です。は、会社の株式の5.15%を直接所有しており、その価値は$ 0.15 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と6.5年です。

主要情報

Sumit Aggarwal

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	3.6yrs
CEOの所有権	5.1%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	6.5yrs

経営陣の近況

Recent updates

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

CEO報酬分析

Eloxx Pharmaceuticals の収益と比較して、Sumit Aggarwal の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$24m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$575k	-US$36m
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$70m
Dec 31 2021	US$6m	US$408k	-US$67m

報酬と市場: Sumitの総報酬がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Sumitの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sumit Aggarwal (51 yo)

3.6yrs

在職期間

US$1,395,942

報酬

Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sumit Aggarwal	President	3.6yrs	US$1.40m	5.15% $ 0.2
Daniel Geffken	Interim CFO	3.6yrs	US$63.96k	0.038% $ 0.001
Barbara Ryan	Investor Relations Officer	no data	データなし	データなし
Ali Hariri	Chief Medical Officer	3yrs	データなし	データなし

3.6yrs

平均在職期間

64yo

平均年齢

経験豊富な経営陣: ELOXの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Sumit Aggarwal	President	3.6yrs	US$1.40m	5.15% $ 0.2
Steven Rubin	Independent Director	6.9yrs	US$58.60k	0.36% $ 0.01
Alan Walts	Independent Director	3.6yrs	US$61.10k	0.39% $ 0.01
Patrick Flume	Member of Medical Advisory Board	no data	データなし	データなし
Timor Baasov	Member of Scientific Advisory Board	no data	データなし	データなし
Noreen Henig	Member of Medical Advisory Board	no data	データなし	データなし
David Bedwell	Member of Scientific Advisory Board	6.5yrs	データなし	データなし
Rachel Green	Member of Scientific Advisory Board	6.5yrs	データなし	データなし
Sudhir Kumar	Member of Scientific Advisory Board	6.5yrs	データなし	データなし
Lynne Maquat	Member of Scientific Advisory Board	6.5yrs	データなし	データなし
Donald Vandevanter	Member of Medical Advisory Board	no data	データなし	データなし
Christiane De Boeck	Member of Medical Advisory Board	no data	データなし	データなし

6.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: ELOXの取締役会は経験豊富であると考えられます ( 6.5年の平均在任期間)。

Eloxx Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

President exercised options and sold US$59k worth of stock

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

New minor risk - Shareholder dilution

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

New major risk - Market cap size

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Price target increased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Price target decreased to US$2.25

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$3.00

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Price target decreased to US$3.00

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President exercised options and sold US$59k worth of stock

Price target increased to US$4.03

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Eloxx Pharmaceuticals EPS misses by $0.06

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

CEO & Director exercised options and sold US$61k worth of stock

New 90-day high: US$4.51

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

New 90-day high: US$3.94

New 90-day low: US$2.42

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.68

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34